Xynomic returns to Boehringer for second cancer candidate

Xynomic Pharmaceuticals (Dover, Del.) gained exclusive, worldwide rights to BI 860585 from Boehringer Ingelheim GmbH (Ingelheim, Germany).

Response from Xynomic Business Development Manager Angela Fung told BioCentury that Xynomic will pay Boehringer up to $800 million total, including an upfront payment, regulatory milestones and potential royalties...